Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
30 January 2017
E-000525-17
Question for written answer
to the Commission
Rule 130
Marina Albiol Guzmán (GUE/NGL)

 Subject:  Approval of Exondys 51 for use in the European Union
 Answer(s) 

The orphan drug Exondys 51 is being used in used in several countries to prevent the development of Duchenne’s Syndrome, which is a degenerative illness leading to muscular dystrophy. The European Medicines Agency (EMA) has yet to approve the drug for use in the EU.

Bearing in mind that this drug can substantially improve the lives of many Europeans, can the Commission state whether it is keeping a watching brief on its approval by the EMA? Does the Commission have any information on when Exondys 51 may be approved?

Original language of question: ES 
Last updated: 20 February 2017Legal notice